Daily Doxycycline to Inform Sexually Transmitted Infection Prophylaxis Regimens

Phase 4 Completed 24 enrolled Emory University Centers for Disease Control and Prevention · collab

NaSingle-groupOpen-labelBasic science

Summary

The goal of this project is to collect data regarding the concentrations of doxycycline in mucosal tissues after daily dosing for 7 days in people assigned male sex at birth (AMAB) and assigned female sex at birth (AFAB) to inform future studies of doxycycline to protect against bacterial sexually transmitted infections (STIs).

Timeline

Start: 2024-09-13
Primary completion: 2025-04-29
Completion: 2025-04-29

Publications

Daly MB, Spandau M, Edwards TE, Dinh C, Fountain J, Dienhart JA, Conway-Washington C, Kelley C, Heneine W, Haaland R. Chelating anticoagulants reduce plasma doxycycline measurements: implications for doxy PEP monitoring. Expert Rev Clin Pharmacol. 2026 Jan-Feb;19(2):199-205. doi: 10.1080/17512433.2026.2632931. Epub 2026 Feb 19.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Doxycycline	Small molecule	100 mg	Oral

Daily Doxycycline to Inform Sexually Transmitted Infection Prophylaxis Regimens

Summary

Timeline

Publications

Drugs

Indications